Therefore, our findings strongly support clinical application of class I PI3K pan-inhibitors rather than dual γ/δ or single-isoform inhibitors for the treatment of the major part of T-ALL patients. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.